Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules

Business Wire September 24, 2018

Verastem Oncology Announces Investigator Sponsored Study on Duvelisib in Combination with Venetoclax

Business Wire September 6, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 4, 2018

Verastem Oncology Appoints Robert E. Gagnon as Chief Financial Officer

Business Wire August 29, 2018

Verastem Oncology Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 8, 2018

Verastem Oncology Reports Second Quarter 2018 Financial Results

Business Wire August 8, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 5, 2018

Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit

Business Wire July 2, 2018

Verastem Oncology to Join Russell 3000® Index

Business Wire June 25, 2018

Verastem Oncology Presents Duvelisib Data at EHA 2018 Annual Meeting

Business Wire June 16, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Companhia Brasileira de Distribuicao, SiteOne Landscape Supply, UGI, Versum Materials, Verastem, and Tanger Factory Outlet Centers — New Research Emphasizes Economic Growth

GlobeNewswire June 15, 2018

Verastem Oncology Announces $43.0 Million Offering of Common Stock

Business Wire June 14, 2018

Verastem Oncology and Yakult Honsha Co., Ltd. Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan

Business Wire June 5, 2018

Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting

Business Wire June 4, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 4, 2018

Thinking about buying stock in Apple, American Eagle Outfitters, Horizon Pharma, Micron or Verastem?

PR Newswire May 31, 2018

Verastem Oncology Announces Closing of Underwriter’s Option to Purchase Additional Shares

Business Wire May 23, 2018

Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology Congress

Business Wire May 21, 2018

Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting

Business Wire May 17, 2018

Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting

Business Wire May 16, 2018